ArticleClinical and experimental medicine2025
Exploring the therapeutic effects of intensified immunosuppressive regimen for preengraftment syndrome after umbilical cord blood transplantation.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Preengraftment syndrome (PES) is a common complication of cord blood transplantation (CBT) that causes an inflammatory storm and organ impairments. Optimal treatment strategies for PES remain unclear.This study aims to explore the therapeutic effects of post-transplant cyclophosphamide (PTCy), etanercept, and methylprednisolone in the treatment of PES. This study included 60 patients who were diagnosed with PES after single umbilical cord blood transplantation between 2016 and 2023. Outcomes were compared between a historical control group (2016-2019, n = 27) treated with methylprednisolone and a cohort that received an intensified immunosuppressive regimen (2020-2023, n = 33) consisting of PTCy, etanercept, and methylprednisolone. The comparison encompassed key clinical outcomes, including hematopoietic engraftment, acute graft-versus-host disease (aGVHD), infection, relapse, and survival. Firstly, the intensified immunosuppressive regimen effectively alleviated the clinical symptoms of PES compared to the historical regimen, as evidenced by significantly higher rates of symptom resolution (fever remission: 75.7% vs. 44.4%, P = 0.006, rash remission: 57.5% vs. 29.6%, P = 0.042). It also reduced glucocorticoid exposure (median: 9 days [IQR 9-9] vs. 13 days [IQR 12-14], P < 0.001), and lowered the incidence of steroid tapering failure (6.1% ± 4.2% vs. 41.4% ± 9.6%, P < 0.001). Secondly, intensified immunosuppressive regimen was a protective factor against grade II-IV aGVHD (HR 0.239 [0.093-0.611], P = 0.008) and grade III-IV aGVHD (HR 0.259 [0.073-0.918], P = 0.036). However, it increased the risk of CMV/EBV infection (42.4% vs.18.5%, P = 0.043). Thirdly, the intensified immunosuppressive regimen had no effect on donor cell engraftment, the recurrence of malignant diseases or survival outcomes. The combination of PTCy, etanercept, and methylprednisolone represents an effective treatment strategy for PES and reduces the incidence of aGVHD, albeit with an increased risk of viral infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.